{"slug":"tb-500-glp1-gut","verification":{"valid":true,"entries":1,"head":"7c6b5f988e0b493315e06694af070cf59c4c4e5572bf9016a010da8602b58f68"},"count":1,"models":["grok/grok-4.3"],"yield":{"passes":1,"energy_spent_rows":0,"total_cost_usd":0.031302,"waste_cost_usd":0,"total_tokens":21770,"material_outputs":0,"usd_per_output":null,"models":[{"model":"grok/grok-4.3","passes":1,"cost_usd":0.031302,"tokens_total":21770,"outputs":0,"waste_passes":0,"usd_per_output":null}],"constraints":{"constitution":"/api/articles/constitution","collaborate_schema":"POST /api/protocol/collaborate","pricing_ppm":{"grok-4.3":[1.25,2.5],"grok/grok-4.3":[1.25,2.5],"grok-build-0.1":[1,2],"kimi/moonshot-v1-8k":[0.15,0.15],"gemini/gemini-2.5-flash":[0.075,0.3],"gemini/gemini-2.0-flash-lite":[0.075,0.3],"openai/gpt-4o":[2.5,10],"openai/gpt-4o-mini":[0.15,0.6],"system/reflex":[0,0],"ingest:deterministic":[0,0],"fill-slots":[0,0]}}},"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:38:03.712Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"TB-500 for GLP-1 Gut Damage and Gastroparesis: What the Evidence Shows","register":"source_ledger","body":"## What's breaking down if you have GLP-1 gut damage / gastroparesis\n\nGLP-1 receptor agonists slow gastric emptying as part of their intended action on gut motility. In some people this effect becomes pronounced and persistent, producing symptoms that overlap with gastroparesis. The core issue is delayed stomach emptying that can lead to nausea, bloating, early satiety, and in rarer cases more serious motility problems.\n\nRepair-versus-degeneration framing applies here. The drug suppresses a motility signal to achieve metabolic benefits. When that suppression outruns the gut's ability to maintain normal function or recover normal motility, the problem persists. No direct tissue destruction occurs in most cases, but prolonged slowed transit can stress the enteric nervous system and smooth muscle layers that coordinate emptying.\n\n## Why TB-500 might help you\n\n1. You are reading about GLP-1 gut damage / gastroparesis — what breaks down matters before any compound name.\n2. What keeps failing: Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\n3. What TB-500 is studied to do: Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\n4. Therefore for you: If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\n\nIf GLP-1 agonist use has left gut motility slowed and local repair processes lagging, the logic chain points to whether actin-based cell movement can be supported. TB-500 fragments of thymosin beta-4 bind actin and are studied in preclinical models for promoting cell migration to sites of tissue stress. That migration step is one of the early requirements for clearing stalled inflammatory signals and allowing structural reorganization of smooth muscle or mucosal layers.\n\nThe if-then is narrow: only if actin disorganization or failed cell recruitment is contributing to your specific motility lag would this pathway be relevant. It does not reverse the GLP-1 receptor signal itself.\n\n## Why GLP-1 agonists (class) matters for you\n\nGLP-1 agonists (class) support metabolism by enhancing insulin response, slowing gastric emptying, and reducing appetite. The same motility slowing that aids glycemic control and weight loss can trade off against normal gut transit in susceptible individuals. This is suppression of a signal rather than reduction of mechanical load. The metabolic support is the primary benefit; any gut slowing is a known mechanism-based effect that usually attenuates but can persist or intensify in some users. For someone already experiencing gastroparesis-like symptoms, the tradeoff is direct: continued use maintains the metabolic benefit while the motility signal remains suppressed.\n\n## How these fit together\n\nSingle-compound focus — TB-500 targets inflammation clearance / repair-cell migration. GLP-1 agonists provide metabolic support at the cost of motility suppression. The two do not directly interact in studied pathways; one addresses downstream repair questions while the other maintains the upstream metabolic change. Any combined discussion stays at the level of separate layers rather than claimed synergy.\n\n## What the evidence actually shows\n\nHuman data on TB-500 or thymosin beta-4 for gut motility or gastroparesis is absent. Scoping reviews of thymosin beta-4 and TB-500 map evidence primarily to wound healing, ocular repair, and vascular contexts, with human trials concentrated in skin/soft tissue and cornea settings (source s10). No included human studies address intestinal smooth muscle or enteric repair.\n\nPreclinical (mostly rodent and cell) work shows thymosin beta-4 promotes cell migration via actin sequestration and supports angiogenesis and reduced fibrosis in various tissues. These findings remain animal or in-vitro and do not establish translation to human GLP-1-related gastroparesis.\n\nGLP-1 agonist effects on gastric emptying are documented in multiple human mechanistic and clinical studies; delayed emptying is a reproducible class effect that can meet diagnostic thresholds for gastroparesis in a subset of users (sources s0, s1, s3).\n\n## What scientists say\n\nResearchers note that thymosin beta-4 is an endogenous actin-sequestering protein with roles in embryonic development and adult tissue repair, yet large-scale randomized human trials for gastrointestinal applications are lacking. Reviews emphasize that while preclinical signals exist for cell migration and inflammation modulation, direct musculoskeletal or gut human evidence is sparse and largely preclinical (source s10). For GLP-1 agonists, clinicians document the motility effect as expected pharmacology rather than an off-target toxicity in most cases, with individual variability in persistence of symptoms.\n\n## What people say on Reddit\n\nAnecdotal reports mention peptides including TB-500 in stacks with BPC-157 for general recovery or gut comfort, but specific accounts tying TB-500 to reversal of GLP-1-induced gastroparesis are rare and unverified. Users sometimes discuss BPC-157 more frequently for GI symptoms, with TB-500 described in broader soft-tissue contexts. Posts note that any perceived gut benefits remain self-reported and coincide with other lifestyle changes (sources s29–s38).\n\n## What people say on X\n\nPublic posts on X echo similar themes: occasional mentions of thymosin beta-4 or TB-500 for tissue repair in general, with very limited discussion of gut-specific outcomes in the context of GLP-1 agonists. No high-visibility threads with documented before-and-after motility testing appear in standard searches.\n\n## What we do not know\n\nWhether TB-500 alters GLP-1 receptor signaling, restores gastric pacemaker activity, or accelerates recovery of enteric neurons after prolonged agonist exposure is unknown. No pharmacokinetic studies examine TB-500 in the setting of concurrent GLP-1 agonist use. Long-term human safety data for TB-500 remain limited outside approved indications for related thymosin compounds.\n\n## Safety and limits\n\nTB-500 is not FDA-approved for any indication. Human clinical trial data are confined to small pilot studies in cardiac or wound settings. Any discussion of its use occurs outside approved medical practice. GLP-1 agonists carry labeled warnings for gastrointestinal effects including delayed emptying; persistent symptoms warrant medical evaluation rather than self-experimentation with research compounds. All claims above are graded by evidence tier and separated by study type; none constitute medical advice.","claims":[{"id":"c1","text":"Thymosin beta-4 / TB-500 evidence is largely preclinical with human data limited to wound/skin and ocular contexts.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s10"],"source_status":"sourced","why_material":"Establishes tier separation between animal and human data for gut applications.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:38:03.327Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"GLP-1 agonists reproducibly delay gastric emptying in humans as a class effect.","section":"What the evidence actually shows","tier":"human","source_ids":["s0","s1","s3"],"source_status":"sourced","why_material":"Documents the mechanistic suppression relevant to the reader's condition.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:38:03.327Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"No human trials exist for TB-500 or thymosin beta-4 in gastroparesis or GLP-1 gut damage.","section":"What we do not know","tier":"human","source_ids":["s10"],"source_status":"sourced","why_material":"Highlights the absence of direct evidence.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:38:03.327Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users discuss TB-500 mainly in general recovery stacks rather than specific GLP-1 gastroparesis reversal.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s29"],"source_status":"sourced","why_material":"Separates community reports from controlled data.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:38:03.327Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s10","type":"review","url":"https://www.mdpi.com/2076-3417/16/12/6202","title":"Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review","quote":"The evidence base was weighted toward mixed and in vitro designs... Human evidence was concentrated in ocular/cornea and wound/skin/soft tissue settings, whereas direct TB-500 evidence was limited to a single included study.","link_status":"http_403","quote_status":"unverified"},{"id":"s0","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11620716/","title":"GLP-1 receptor agonists and delayed gastric emptying","quote":"This paper explores the intricate connection between GLP-1 and delayed gastric emptying, specifically gastroparesis.","link_status":"ok","quote_status":"unverified"},{"id":"s1","type":"review","url":"https://academic.oup.com/jcem/article/110/1/1/7824836","title":"Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide","quote":"While the mechanisms by which GLP-1 and GLP-1RAs affect intestinal motility remain to be defined, they appear to inhibit gastrointestinal motor function through...","link_status":"http_403","quote_status":"unverified"},{"id":"s3","type":"other","url":"https://www.fellahealth.com/guide/incidence-of-gastroparesis-with-glp-1","title":"Incidence of Gastroparesis with GLP-1 Medications","quote":"GLP-1 receptor agonists intentionally slow gastric emptying as part of their therapeutic mechanism...","link_status":"ok","quote_status":"unverified"},{"id":"s29","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/1b7mwv8/how_many_of_you_have_experienced_permanent/","title":"How many of you have experienced permanent intestinal...","quote":"There is a glp-1 protein drink by Biocare that contains enzymes. Perhaps my story is not unique then?","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":18498,"tokens_out":3272,"cost":0.0313025,"prev_hash":"genesis","hash":"7c6b5f988e0b493315e06694af070cf59c4c4e5572bf9016a010da8602b58f68"}]}